Mike Dybbs

Mike Dybbs has over 15 years of investment and consulting experience in the life science sector. He is currently a Partner at Samsara BioCapital where he invests across all stages of the life science sector from seed stage to public equities.

Prior to joining Samsara, Dr. Dybbs was a Partner at New Leaf Venture Partners. Before New Leaf, Dr. Dybbs was a Principal at The Boston Consulting Group, where he was a core member of their Health Care practice. Dr. Dybbs currently serves as a director of companies including: Enara Bio, IONpath, Levo Therapeutics, Nkarta Therapeutics and Sutro (STRO). Previously, he has served on the boards of companies including, Dimension Therapeutics (DMTX), Principia (PRNB) Versartis (VSAR), and Advanced Cell Diagnostics.

He earned a PhD in Molecular and Cellular Biology and Genetics from University of California, Berkeley, where he was awarded a Howard Hughes Medical Institute fellowship; and received an AB in Biomedical Sciences, magna cum laude, from Harvard University. His research had been published in peer-reviewed journals, including Science, Nature and Neuron.